ProductOverview:

HPGM™ HematopoieticGrowthMediumisachemicallydefined,serum-free,xeno-freemediadeveloped tosupport(withtheadditionofappropriatecytokines)theproliferationanddifferentiationofCD34+hematopoieticstemcells(HSC)and hematopoietic Progenitorcells(HPC).HPGM™ HematopoieticGrowthMediumdoesnotcontainanyexogenousgrowthfactors,artificialstimulatorsofcellularproliferation,orundefinedsupplements.HPGM™ HematopoieticGrowthMedium"sformulationiscompleteandcontainshumanalbumin,recombinanthumaninsulin,andpasteurizedhumantransferrin.HPGM™ HematopoieticGrowthMedium maybefurthersupplementedwithadditionalcytokinesandgrowthfactorsdependingonapplications.

HPGM™ HematopoieticGrowthMediumhasbeensuccessfullyusedinthe culturingof CD34+cellsfromavarietyofsourcesincludingbonemarrow,cordblood,peripheralblood,andfetalliverandavarietyofspeciesincludingbothmouseandhumans.HPGM™ HematopoieticGrowthMediumhasbeensuccessfullyusedinthe differentiationof CD34+cellsdownavarietyoflineagesincludingerythroidandmegakaryocyte.

LonzaguaranteestheperformanceofClonetics™/Poietics™cellsonlyifappropriateClonetics™/Poietics™mediaandreagentsareusedexclusivelyandtherecommendedstorageanduseprotocolsarefollowed.Anymodificationsmadetotherecommendedcellsystemsincludingtheuseofalternativemedia,reagentsorprotocols,willvoidcellandmediaperformanceguarantees.Ifyouneedassistanceinselectingtheappropriatemedia,reagents,orprotocol,pleasecontactLonzaScientificSupport.

龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach，公司经营范围包括：生物技术开发服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术推广服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术咨询、交流服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术转让服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;医学研究和试验发展（人体干细胞、基因诊断与治疗技术除外）;药品研发（人体干细胞、基因诊断与治疗技术除外）;货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易（涉及外资准入特别管理规定和许可审批的商品除外）;生物药品制造;化学药品原料药制造;化学药品制剂制造等。